SCHEMBL5879992

SCHEMBL5879992

Cc1ccc(S(=O)(=O)NN=Cc2ccccc2OS(=O)(=O)c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.58
LMNA P02545 6/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
CYP3A4 P08684 3/20 0.58
CYP2C9 P11712 3/20 0.58
CYP2C19 P33261 3/20 0.58
CYP1A2 P05177 2/20 0.58
HTT P42858 2/20 0.58
MAPK1 P28482 1/20 0.58
ALDH1A1 P00352 8/20 0.54
NPSR1 Q6W5P4 4/20 0.54
GAA P10253 3/20 0.54
PKM P14618 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.48
KDM4E B2RXH2 1/20 0.47
RECQL P46063 1/20 0.47
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879987 1.00 MAPT (0.58) MAPTLMNAMEN1KMT2ACYP3A4
SCHEMBL5879610 0.92 GAA (0.53) MAPTLMNAMEN1KMT2ACYP3A4
SCHEMBL5879609 0.92 GAA (0.53) MAPTLMNAMEN1KMT2ACYP3A4
SCHEMBL5879965 0.89 MAPT (0.50) MAPTLMNAMEN1KMT2ACYP3A4
SCHEMBL5879968 0.89 MAPT (0.50) MAPTLMNAMEN1KMT2ACYP3A4
SCHEMBL6375082 0.82 MAPT (0.42) MAPTLMNAMEN1KMT2ACYP3A4
SCHEMBL5880011 0.82 MAPT (0.42) MAPTLMNAMEN1KMT2ACYP3A4
SCHEMBL5880128 0.81 MAPT (0.58) MAPTLMNAMEN1KMT2AHTT
SCHEMBL5880124 0.81 MAPT (0.58) MAPTLMNAMEN1KMT2AHTT
SCHEMBL5880042 0.81 LMNA (0.45) MAPTLMNAMEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US claimed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US claimed
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 MAPT 4629/4885LMNA 4281/4885MEN1 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.